JP2008517991A5 - - Google Patents

Download PDF

Info

Publication number
JP2008517991A5
JP2008517991A5 JP2007538524A JP2007538524A JP2008517991A5 JP 2008517991 A5 JP2008517991 A5 JP 2008517991A5 JP 2007538524 A JP2007538524 A JP 2007538524A JP 2007538524 A JP2007538524 A JP 2007538524A JP 2008517991 A5 JP2008517991 A5 JP 2008517991A5
Authority
JP
Japan
Prior art keywords
effective amount
therapeutically effective
pld
combination
administration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2007538524A
Other languages
English (en)
Japanese (ja)
Other versions
JP4554684B2 (ja
JP2008517991A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/GB2005/050189 external-priority patent/WO2006046080A2/en
Publication of JP2008517991A publication Critical patent/JP2008517991A/ja
Publication of JP2008517991A5 publication Critical patent/JP2008517991A5/ja
Application granted granted Critical
Publication of JP4554684B2 publication Critical patent/JP4554684B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

JP2007538524A 2004-10-26 2005-10-26 抗癌治療 Expired - Lifetime JP4554684B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US62216304P 2004-10-26 2004-10-26
PCT/GB2005/050189 WO2006046080A2 (en) 2004-10-26 2005-10-26 Pegylated liposomal doxorubicin in combination with ecteinescidin 743

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2009219607A Division JP2009292850A (ja) 2004-10-26 2009-09-24 抗癌治療

Publications (3)

Publication Number Publication Date
JP2008517991A JP2008517991A (ja) 2008-05-29
JP2008517991A5 true JP2008517991A5 (enExample) 2008-11-13
JP4554684B2 JP4554684B2 (ja) 2010-09-29

Family

ID=36096124

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2007538524A Expired - Lifetime JP4554684B2 (ja) 2004-10-26 2005-10-26 抗癌治療
JP2009219607A Pending JP2009292850A (ja) 2004-10-26 2009-09-24 抗癌治療

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2009219607A Pending JP2009292850A (ja) 2004-10-26 2009-09-24 抗癌治療

Country Status (26)

Country Link
US (1) US20090117176A1 (enExample)
EP (1) EP1827500B1 (enExample)
JP (2) JP4554684B2 (enExample)
KR (1) KR101287918B1 (enExample)
CN (1) CN101119750B (enExample)
AT (1) ATE430586T1 (enExample)
AU (1) AU2005298364B2 (enExample)
BR (1) BRPI0518250A2 (enExample)
CA (1) CA2582452C (enExample)
CY (1) CY1110329T1 (enExample)
DE (1) DE602005014380D1 (enExample)
DK (1) DK1827500T3 (enExample)
ES (1) ES2326825T3 (enExample)
HR (1) HRP20090345T1 (enExample)
IL (1) IL182352A (enExample)
MX (1) MX2007004744A (enExample)
NO (1) NO328958B1 (enExample)
NZ (1) NZ554765A (enExample)
PL (1) PL1827500T3 (enExample)
PT (1) PT1827500E (enExample)
RS (1) RS50822B (enExample)
RU (1) RU2359700C2 (enExample)
SI (1) SI1827500T1 (enExample)
UA (1) UA87877C2 (enExample)
WO (1) WO2006046080A2 (enExample)
ZA (1) ZA200703396B (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY164077A (en) 1999-05-13 2017-11-30 Pharma Mar Sa Compositions and uses of et743 for treating cancer
MXPA02011319A (es) 2000-05-15 2003-06-06 Pharma Mar Sa Analogos antitumorales de ecteinascidina 743.
US20040108086A1 (en) * 2000-11-06 2004-06-10 Naoto Takahashi Effective antitumor treatments
GB0117402D0 (en) * 2001-07-17 2001-09-05 Pharma Mar Sa New antitumoral derivatives of et-743
GB0202544D0 (en) 2002-02-04 2002-03-20 Pharma Mar Sa The synthesis of naturally occuring ecteinascidins and related compounds
SI1689404T1 (sl) 2003-11-13 2009-02-28 Pharma Mar Sau Kombinacija et-743 s 5-fluorouracil pro zdravili za zdravljenje raka
US20080255132A1 (en) * 2003-11-14 2008-10-16 Eric Rowinsky Combination Therapy Comprising the Use of Et-743 and Paclitaxel for Treating Cancer
RS50510B (sr) 2004-10-29 2010-03-02 Pharma Mar S.A., Sociedad Unipersonal Formulacije koje sadrže ekteinascidin i disaharid
GB0522082D0 (en) * 2005-10-31 2005-12-07 Pharma Mar Sa Formulations
US8444963B2 (en) 2006-06-19 2013-05-21 John Hopkins University Tumor specific delivery of therapeutic agents via liposomase
US20100267732A1 (en) * 2007-10-19 2010-10-21 Pharma Mar, S.A. Prognostic Molecular Markers for ET-743 Treatment
US11110108B2 (en) 2016-09-27 2021-09-07 Vertex Pharmaceuticals Incorporated Method for treating cancer using a combination of DNA-damaging agents and DNA-PK inhibitors
JOP20190254A1 (ar) 2017-04-27 2019-10-27 Pharma Mar Sa مركبات مضادة للأورام
RU2657835C1 (ru) * 2017-11-28 2018-06-15 Федеральное государственное автономное образовательное учреждение высшего образования "Национальный исследовательский технологический университет "МИСиС" Способ получения системы для доставки противоопухолевого препарата в клетки опухоли

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5149804A (en) * 1990-11-30 1992-09-22 The Board Of Trustees Of The University Of Illinois Ecteinascidins 736 and 722
US5256663A (en) * 1986-06-09 1993-10-26 The Board Of Trustees Of The University Of Illinois Compositions comprising ecteinascidins and a method of treating herpes simplex virus infections therewith
US5089273A (en) * 1986-06-09 1992-02-18 Board Of Trustees Of The University Of Illinois Ecteinascidins 729, 743, 745, 759A, 759B and 770
DE3635711A1 (de) * 1986-10-21 1988-04-28 Knoll Ag 5-nitrobenzo(de)isochinolin-1,3-dione, ihre herstellung und verwendung
US5013556A (en) * 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
FR2697752B1 (fr) * 1992-11-10 1995-04-14 Rhone Poulenc Rorer Sa Compositions antitumorales contenant des dérivés du taxane.
US5478932A (en) * 1993-12-02 1995-12-26 The Board Of Trustees Of The University Of Illinois Ecteinascidins
US20040059112A1 (en) * 1994-02-18 2004-03-25 Rinehart Kenneth L. Ecteinascidins
GB9508195D0 (en) * 1995-04-20 1995-06-07 Univ British Columbia Novel biologically active compounds and compositions,their use and derivation
US6245805B1 (en) * 1995-10-26 2001-06-12 Baker Norton Pharmaceuticals, Inc. Method, compositions and kits for increasing the oral bioavailability of pharmaceutical agents
US5721362A (en) * 1996-09-18 1998-02-24 President And Fellows Of Harvard College Process for producing ecteinascidin compounds
US5985876A (en) * 1997-04-15 1999-11-16 Univ Illinois Nucleophile substituted ecteinascidins and N-oxide ecteinascidins
CZ301083B6 (cs) * 1998-04-06 2009-11-04 The Board Of Trustees Of The University Of Illinois Ekteinascidinová sloucenina, farmaceutický prostredek ji obsahující a její použití
US6124292A (en) * 1998-09-30 2000-09-26 President And Fellows Of Harvard College Synthetic analogs of ecteinascidin-743
MY164077A (en) * 1999-05-13 2017-11-30 Pharma Mar Sa Compositions and uses of et743 for treating cancer
MY130271A (en) * 1999-05-14 2007-06-29 Pharma Mar Sa Hemisynthetic method and new compounds
US20020028237A1 (en) * 2000-04-20 2002-03-07 Colbern Gail T. Method for reducing toxicity of a cytotoxic agent
US7247892B2 (en) * 2000-04-24 2007-07-24 Taylor Geoff W Imaging array utilizing thyristor-based pixel elements
US7420051B2 (en) * 2000-05-15 2008-09-02 Pharma Mar, S.A. Synthetic process for the manufacture of an ecteinaschidin compound
MXPA02011319A (es) * 2000-05-15 2003-06-06 Pharma Mar Sa Analogos antitumorales de ecteinascidina 743.
CA2418320A1 (en) * 2000-08-11 2002-02-21 City Of Hope The anti-neoplastic agent et-743 inhibits trans activation by sxr
ATE314084T1 (de) * 2000-10-31 2006-01-15 Pharma Mar Sa Kahalalid f formulierung
US20040108086A1 (en) * 2000-11-06 2004-06-10 Naoto Takahashi Effective antitumor treatments
HUP0303466A3 (en) * 2001-03-06 2005-02-28 Bristol Myers Squibb Company P Method and dosage form for treating tumors by administration of tegafur, uracil, folinic acid, paclitaxel and carboplatin
EP1401396A4 (en) * 2001-06-15 2009-08-05 Cornerstone Pharmaceuticals PHARMACEUTICAL AND DIAGNOSTIC COMPOSITIONS WITH NANOPARTICLES FOR THE TREATMENT OF TARGET TISSUE AND CELLS
KR20050038578A (ko) * 2001-10-19 2005-04-27 파르마 마르, 에스.에이. 항종양성 화합물의 암치료에 있어서의 향상된 용도
US20040019027A1 (en) * 2002-04-12 2004-01-29 Barry Forman Method of treating cerebrotendinous xanthomatosis
AU2003253954A1 (en) * 2002-07-16 2004-02-02 Alfred E. Mann Institute For Biomedical Engineering At The University Of Southern California Support bra for ultrasonic breast scanner
GB0312407D0 (en) * 2003-05-29 2003-07-02 Pharma Mar Sau Treatment
GB0324201D0 (en) * 2003-10-15 2003-11-19 Pharma Mar Sau Improved antitumoral combinations
SI1689404T1 (sl) * 2003-11-13 2009-02-28 Pharma Mar Sau Kombinacija et-743 s 5-fluorouracil pro zdravili za zdravljenje raka
GB0326486D0 (en) * 2003-11-14 2003-12-17 Pharma Mar Sau Combination treatment
US20080255132A1 (en) * 2003-11-14 2008-10-16 Eric Rowinsky Combination Therapy Comprising the Use of Et-743 and Paclitaxel for Treating Cancer
US20050129752A1 (en) * 2003-12-15 2005-06-16 Tty Biopharm Limited Company Use and manufacturing process for liposomal doxorubicin pharmaceutical composition
US20080293725A1 (en) * 2004-07-09 2008-11-27 Rafael Rosell Costa Prognostic Molecular Markers
RS50510B (sr) * 2004-10-29 2010-03-02 Pharma Mar S.A., Sociedad Unipersonal Formulacije koje sadrže ekteinascidin i disaharid
WO2007062413A2 (en) * 2005-11-25 2007-05-31 University Of Medicine And Dentistry Of New Jersey Use of parp-1 inhibitors
US20080075772A1 (en) * 2006-04-13 2008-03-27 Lawrence Solomon Pharmaceutical compositions having novel scoring patterns and methods of using those compositions
WO2007134203A2 (en) * 2006-05-12 2007-11-22 Pharma Mar, S.A. Anticancer treatments with a combination of docetaxel and ecteinascidin

Similar Documents

Publication Publication Date Title
RU2010133489A (ru) Применение ингибиторов гамма-секретазы для лечения рака
JP2009539769A5 (enExample)
JP2008517991A5 (enExample)
PL350313A1 (en) Apomorphine and sildenafil composition
HRP20170056T2 (hr) Terapija male učestalosti glatiramer acetatom
JP2010519224A5 (enExample)
JP2002544231A5 (enExample)
JP2008520544A5 (ja) 癌関連疲労の治療または予防のための医薬の製造への使用方法
AU2014299699A1 (en) Use of eribulin and lenvatinib as combination therapy for treatment of cancer
JP2017132791A (ja) 組み合わせ組成物
JP2006514092A5 (enExample)
JP2009515901A5 (enExample)
CA2582452A1 (en) Pegylated liposomal doxorubicin in combination with ecteinascidin 743
RU2007101695A (ru) Лекарственный препарат для лечения сахарного диабета на основе экзенатида и даларгина, применение и способ лечения
JP2005508963A5 (enExample)
JP2008540364A5 (enExample)
RU2005126819A (ru) Усовершенствованное лечение опухолей
WO2005094899A8 (en) Clusterin antisense therapy for treatment of cancer
JP2003514025A5 (enExample)
ES2267841T3 (es) Uso de una derivado de alfa-halogeno-acriloil distamicina para la preparacion de un medicamento para el tratamiento del cancer.
JP2002540148A5 (enExample)
CA2474430A1 (en) A combination of a thrombolytic agent and levosimendan for the treatment of acute myocardial infarction
CA2450915A1 (en) Use of levosimendan and beta-adrenergic receptor antagonist for the treatment of heart failure
CA2516458A1 (en) Use of kahalalide compounds for the manufacture of a medicament for the treatment of psoriasis
JP2015510945A5 (enExample)